Delayed Graft Function clinical trials at UCSF
1 research study open to eligible people
Delayed graft function means a new kidney takes longer to work after a transplant. UCSF is conducting studies to test Ravulizumab, a drug given through an IV. These trials will evaluate its effect on patients at high risk of delayed kidney function.
Showing trials for
Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
open to eligible people ages 18 years and up
The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.
San Francisco, California and other locations
Last updated: